NCT04621643

Brief Summary

Sleep is a fundamental human need with large impact on both psychological and somatic functioning. However, for patients with mental disorders, sleep is often disturbed. Across all diagnostic groups, sleep disturbance is one of the most common and disruptive symptoms. For decades it has been assumed that the sleep disturbance these patients experience was a secondary symptom of a primary mental disorder, but recently this has changed. Experimental and clinical data now suggest that there is a reciprocal relationship between sleep disturbance and mental disorders where they perpetuate and aggravate each other. This makes sleep disturbance a potential therapeutic target in the treatment of mental disorders. Evidence emerging the last decade indicate that providing Cognitive Behavior Therapy for Insomnia (CBT-I) to patients with mental disorders not only improves sleep, but also has clinically meaningful effects on their primary mental disorder. However, a major problem has been disseminating CBT-I and few therapists are trained in this intervention. Consequently, most patients receive sleep medication although evidence clearly indicate that CBT-I is more effective and should be the treatment of choice. In this study, the investigators will use a fully automated digital version of CBT-I that might be used to treat a large number of patients while they are still on the waiting list to receive ordinary outpatient treatment in secondary mental health care clinics in Norway. The main goal is to test the effectiveness of digital CBT-I for this patient group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
911

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 17, 2020

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 9, 2020

Completed
15 days until next milestone

Study Start

First participant enrolled

November 24, 2020

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

February 26, 2025

Status Verified

February 1, 2025

Enrollment Period

3.6 years

First QC Date

September 17, 2020

Last Update Submit

February 25, 2025

Conditions

Keywords

Cognitive Behavioral TherapyPatient EducationTelemedicineWaiting Lists

Outcome Measures

Primary Outcomes (1)

  • Between-group difference in insomnia severity at week 9 after randomization

    Assessed with the Insomnia Severity Index (ISI), a 7-item questionnaire for the severity of insomnia symptoms the last 14 days. Each item is rated on a 0 to 4 rating scale with higher scores indicating more severe symptoms. The ISI has good psychometric properties and is validated for online use. Range is 0-28 with higher values represent higher levels of insomnia symptom severity.

    9 weeks after randomization

Secondary Outcomes (48)

  • Between-group difference in insomnia severity at week 33 after randomization

    33 weeks after randomization

  • Between-group difference in insomnia severity at week 61 after randomization

    61 weeks after randomization

  • Prospective daily sleep-wake pattern at week 9 after randomization

    9 weeks after randomization

  • Prospective daily sleep-wake pattern at week 33 after randomization

    33 weeks after randomization

  • Prospective daily sleep-wake pattern at week 61 after randomization

    61 weeks after randomization

  • +43 more secondary outcomes

Study Arms (2)

digital cognitive behavioral therapy (dCBT-I)

EXPERIMENTAL
Behavioral: digital cognitive behavioral therapy (dCBT-I)

Patient education about sleep (PE)

ACTIVE COMPARATOR
Behavioral: Digital patient education about insomnia (PE)

Interventions

dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices

digital cognitive behavioral therapy (dCBT-I)

Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.

Patient education about sleep (PE)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Willing and able to provide written informed consent.
  • Insomnia Severity Index (ISI) \> 11 We have used this cut-off score previously to identify individuals who are likely to be experiencing clinical significant insomnia and who will potentially benefit from the dCBT-I intervention. Kallestad et al 2018 and a trial from Norway (Filosa et al in press) suggest that this cut-off is the most sensitive to detect a diagnosis of Insomnia Disorder.

You may not qualify if:

  • Sleep apnea screening: Positive endorsement of a screening question for sleep apnea (the item asks if they "usually or everyday snore and stop breathing and have difficulties staying awake during the day")
  • Medical history indicative of (i) epilepsy plus self-report of \>=1 seizure \<12 months ago, or (ii) recent surgery for heart disease, or (iii) currently in an attack phase of multiple sclerosis.
  • Individuals whose work schedule includes night shifts.
  • Pregnancy
  • Inadequate opportunity to sleep or circumstances prevent modification of sleep pattern (e.g. having a child aged\<12 months residing home).
  • Currently receiving psychological treatment for insomnia.
  • Not a patient at one of the participating clinics.
  • Not having completed baseline assessment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Helse Møre og Romsdal HF

Ålesund, Norway

Location

AHUS

Oslo, Norway

Location

Stavanger Universitetssykehus

Stavanger, Norway

Location

St Olavs Hospital

Trondheim, Norway

Location

Related Publications (1)

  • Kallestad H, Saksvik S, Vedaa O, Langsrud K, Morken G, Lydersen S, Simpson MR, Dorheim SK, Holmoy B, Selvik SG, Hagen K, Stiles TC, Harvey A, Ritterband L, Sivertsen B, Scott J. Digital cognitive-behavioural therapy for insomnia compared with digital patient education about insomnia in individuals referred to secondary mental health services in Norway: protocol for a multicentre randomised controlled trial. BMJ Open. 2021 Jun 28;11(6):e050661. doi: 10.1136/bmjopen-2021-050661.

MeSH Terms

Conditions

Mental DisordersSleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Pål Sandvik, md

    St Olavs Hospital, Division of Mental Health Care

    STUDY DIRECTOR
  • Håvard Kallestad, phd

    Norwegian University of Science and Technology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Participants are blinded to their group allocation, but complete blinding is not possible as the participants may understand whether they have received the active or control condition.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2020

First Posted

November 9, 2020

Study Start

November 24, 2020

Primary Completion

June 30, 2024

Study Completion

June 30, 2024

Last Updated

February 26, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

Anonymized data that underlie the results will be available after publication of the final version of the trial to researchers from accredited research institutions. Access to data will be limited to investigators who provide a methodologically sound proposal and will be for a specified time period (commencing about 3 months after publication and ending after five years). To ensure GDPR compliance, data processing must be covered by the 'Standard Contractual Clauses' from the European Commission, that data requesters have to sign. Proposals and requests for data access should be directed to the principal investigator.

Locations